River & Mercantile Asset Management LLP boosted its holdings in shares of Mylan NV (NASDAQ:MYL) by 25.6% in the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 81,171 shares of the company’s stock after buying an additional 16,529 shares during the quarter. River & Mercantile Asset Management LLP’s holdings in Mylan were worth $2,971,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other hedge funds and other institutional investors have also made changes to their positions in MYL. Stratos Wealth Partners LTD. bought a new stake in Mylan during the third quarter valued at approximately $183,000. FTB Advisors Inc. bought a new position in shares of Mylan in the second quarter worth approximately $188,000. Reilly Financial Advisors LLC boosted its position in shares of Mylan by 69.4% in the third quarter. Reilly Financial Advisors LLC now owns 5,217 shares of the company’s stock worth $191,000 after purchasing an additional 2,137 shares during the period. BB&T Corp bought a new position in shares of Mylan in the third quarter worth approximately $202,000. Finally, Sustainable Insight Capital Management LLC bought a new position in shares of Mylan in the third quarter worth approximately $226,000. Institutional investors own 82.17% of the company’s stock.
Shares of NASDAQ:MYL opened at $30.55 on Friday. The company has a debt-to-equity ratio of 1.20, a current ratio of 1.26 and a quick ratio of 0.77. Mylan NV has a fifty-two week low of $30.33 and a fifty-two week high of $47.82. The firm has a market cap of $16.42 billion, a P/E ratio of 6.70, a P/E/G ratio of 1.05 and a beta of 1.49.
A number of equities analysts have weighed in on MYL shares. Cantor Fitzgerald reiterated a “hold” rating and issued a $41.00 price target on shares of Mylan in a research report on Monday, November 5th. ValuEngine upgraded shares of Mylan from a “sell” rating to a “hold” rating in a research report on Tuesday, August 14th. Royal Bank of Canada upgraded shares of Mylan from a “sector perform” rating to an “outperform” rating and set a $53.00 price target for the company in a research report on Monday, August 13th. Morgan Stanley lowered shares of Mylan from an “overweight” rating to an “equal weight” rating and dropped their price target for the stock from $46.00 to $36.00 in a research report on Tuesday, October 9th. Finally, Mizuho lowered shares of Mylan from a “buy” rating to a “neutral” rating in a research report on Friday, October 5th. Two analysts have rated the stock with a sell rating, five have given a hold rating and fourteen have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $46.56.
Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, brand name, and over-the-counter (OTC) products worldwide. The company operates through three segments: North America, Europe, and Rest of World. It offers pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, nebulized, and cream or ointment forms.
Featured Story: Trading Penny Stocks
Want to see what other hedge funds are holding MYL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mylan NV (NASDAQ:MYL).
Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with MarketBeat.com's FREE daily email newsletter.